⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423569 | 0.85 | THRB (0.46) | — | |
| SCHEMBL1477815 | 0.74 | — | — | |
| SCHEMBL5161658 | 0.71 | — | — | |
| SCHEMBL378118 | 0.69 | — | — | |
| SCHEMBL9773548 | 0.68 | — | — | |
| SCHEMBL20639285 | 0.67 | THRB (0.35) | — | |
| SCHEMBL14706244 | 0.65 | — | — | |
| SCHEMBL3148945 | 0.65 | — | — | |
| SCHEMBL12678301 | 0.65 | ALDH1A1 (0.30) | — | |
| SCHEMBL17707240 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1643 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | claimed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | claimed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | claimed |
| EP-3670515-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-10597382-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | claimed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | claimed |
| US-10081639-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-09-25 | — | — | US | claimed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | claimed |
| US-9856249-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2018-01-02 | — | — | US | claimed |
| EP-2379559-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2017-10-25 | — | — | EP | claimed |
| EP-2806875-B1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | claimed |
| US-9346785-B2 | Process for making HCV protease inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | claimed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | claimed |
| US-8785487-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | claimed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024137764-A1 | NOVEL COVALENT INHIBITORS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240207224-A1 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-110944990-B | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111372583-B | Artemisinin-derived trimers and tetramers and uses thereof | 赵鸣 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2024-06-13 | — | — | US | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-12006326-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3544957-B1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11993600-B2 | Saturated spirocyclics as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024107783-A2 | NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-114423766-B | Pentane derivatives for the treatment of bacterial infections | 丹诺医药(苏州）有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-118043045-A | Novel spiropyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11976084-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240140984-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| EP-4358957-A1 | (1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL--ACRYLAMIDE INHIBITORS OF EGFR FOR USE IN THE TREATMENT OF BRAIN TUMORS | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11970502-B2 | Macrocyclic antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240132476-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-11964942-B2 | SSAO inhibitors and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2024-04-23 | — | — | US | disclosed |
| EP-4351578-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | Stinginn Inc (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11958879-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240116894-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11945824-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945816-B2 | Inhibitors of EGFR and/or HER2 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945830-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11945790-B2 | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-113710276-B | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11939300-B2 | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112312905-B | Tetrazole-containing inhibitors of apoptosis signal-regulating kinase 1 and methods of use thereof | 英安塔制药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3670515-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11919910-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-110785419-B | Aromatic hydrocarbon receptor antagonist and application thereof | 博雅缉因（北京）生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912695-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3889145-B1 | 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2024-02-21 | — | — | EP | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-11897888-B1 | Small molecular inhibitors of sting signaling compositions and methods of use | STINGINN LLC (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043445-A1 | Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| EP-4308724-A1 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | Becton, Dickinson and Company (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | Life Technologies Corporation | 2024-01-04 | — | — | US | disclosed |
| EP-4298103-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117321221-A | Isothermal amplification of pathogens | 贝克顿迪金森公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230416268-A1 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-3157929-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | ARES TRADING SA (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-117222631-A | Phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-phenyl-, phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-heteroaryl-or phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1H-benzo [ D ] imidazole-carboxylic acid derivatives and methods of use thereof | 诚益生物(美国)公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230391758-A1 | MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-3755689-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365620-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-117043166-A | Antiviral heterocyclic compounds | 英安塔制药有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023211997-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023212019-A1 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023196454-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20230312447-A1 | METHOD OF PREPARING TRITERPENOID COMPOUND | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-10-05 | — | — | US | disclosed |
| CN-116829571-A | Novel spiral pyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023177854-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-111971278-B | Quinoline compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-116547294-A | Functionalized peptides as antiviral agents | 英安塔制药有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-111343990-B | Benzodiazepine-2-one and benzodiazepine-2-one derivatives | 英安塔制药有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230227418-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-07-20 | — | — | US | disclosed |
| US-11691945-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116390926-A | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of use thereof | 上海诚益生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4200288-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | ImmunoMolecular Therapeutics, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-116348477-A | Functionalized peptides as antiviral agents | 英安塔制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116283925-A | Iminophenazine derivative coupling molecule for treating bacterial infection and application thereof | 丹诺医药(苏州）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196117-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198031-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| CN-113768870-B | Artesunate-containing composition and application thereof | 赵鸣 | 2023-06-20 | — | — | CN | disclosed |
| WO-2023107417-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-3472156-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230165873-A1 | Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19 | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-110809472-B | Process for preparing benzodiazepine derivatives | 英安塔制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023086352-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150925-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110869017-B | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-110612105-B | Process for preparing carbamate sulfonic acid bile acid derivatives | 英安塔制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11629134-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2023-04-18 | — | — | US | disclosed |
| US-20230115107-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230115580-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230113570-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | STINGTHERA INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230103494-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11596611-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| EP-3724180-B1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA FARBER CANCER INST INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | ECCOGENE INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-11578097-B2 | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578075-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| WO-2023287740-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11555032-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11542246-B2 | Quinoline compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
| WO-2022271861-A1 | (1H-PYRROLO[2,3-B]PYRIDIN-1-YL)PYRIMIDIN-2-YL-AMINO-PHENYL--ACRYLAMIDE INHIBITORS OF EGFR FOR USE IN THE TREATMENT OF BRAIN TUMORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-109311869-B | Degradation of CDK8 by conjugation of cyclin-dependent kinase 8 (CDK 8) inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220402925-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402966-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-3440084-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220389004-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | EMD Serono Research and Development Institute, Inc. | 2022-12-08 | — | — | US | disclosed |
| US-20220380377-A1 | NOVEL MACROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-01 | — | — | US | disclosed |
| CN-115322193-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-109563075-B | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11447467-B2 | Compounds for the degradation of STK4 and treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-111032655-B | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003296-A | Compounds and methods for treating cystic fibrosis | 弗拉特利发现实验室有限责任公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220273613-A1 | COMPOSITION CONTAINING ARTESUNATE | ZHAO MING (US) | 2022-09-01 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114901649-A | SSAO inhibitors and uses thereof | 上海诚益生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220227746-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220227761-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. | 2022-07-21 | — | — | US | disclosed |
| EP-4028404-A2 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Tennor Therapeutics Limited (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| CN-114761016-A | Antiviral heterocyclic compounds | 英安塔制药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| US-11358953-B2 | Functionalized peptides as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358970-B2 | Artemisinin-derived trimers and tetramers and their use thereof | ZHAO MING (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3582784-B1 | PROCESSES FOR THE PREPARATION OF BENZODIAZEPINE DERIVATIVES | ENANTA PHARM INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3445764-B1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-109071552-B | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use | 达纳－法伯癌症研究所公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11345699-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162217-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220162231-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-114524821-A | Novel spiropyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3500569-B1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114423766-A | Penicilliane derivatives for the treatment of bacterial infections | 丹诺医药(苏州）有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022086840-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114391015-A | Benzo [ b ] [1,8] naphthyridineacetic acid derivatives and methods of use | 斯汀塞拉股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220119366-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3985006-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114302875-A | Oxoacridinylacetic acid derivatives and methods of use | 斯汀塞拉股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-108200760-B | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11279707-B2 | NEK inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022040508-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220055994-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3445760-B1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11254664-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022036018-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220048944-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247991-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-106573937-B | Pyrazole compounds as FSHR modulators and uses thereof | 阿瑞斯贸易股份公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236108-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3350170-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941525-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| CN-108290879-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-109475528-B | Bifunctional molecules for EGFR degradation and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3544975-B1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND USE | DANA FARBER CANCER INST INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3317273-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-113768870-A | Artesunate-containing composition | 赵鸣 | 2021-12-10 | — | — | CN | disclosed |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210379113-A1 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| CN-108602776-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-111263586-B | Hepatitis B antiviral agent | 英安塔制药有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210369749-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113710276-A | Benzodiazepine derivatives as RSV inhibitors | 英安塔制药有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210355119-A1 | CYANO QUINOLINE AMIDE COMPOUNDS AS HER2 INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210346395-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-11-11 | — | — | US | disclosed |
| CN-113603675-A | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20210340140-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-04 | — | — | US | disclosed |
| WO-2021222350-A1 | METHODS OF USE FOR SINGLE MOLECULE COMPOUNDS PROVIDING MULTI-TARGET INHIBITION TO TREAT COVID-19 | SIGNALRX PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| CN-108137559-B | Pyrimidine derivatives as BTK inhibitors and uses thereof | 默克专利有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-113563332-A | Novel pyrimidines as EGFR inhibitors and methods of treating disorders | 达纳－法伯癌症研究所公司 | 2021-10-29 | — | — | CN | disclosed |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3892272-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| CN-109152763-B | Artesunate-containing composition | 赵鸣 | 2021-10-01 | — | — | CN | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-20210300939-A1 | Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof | SIGNALRX PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3883570-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210292320-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021188414-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3874027-A2 | METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | Magenta Therapeutics, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-109069488-B | Hepatitis B antiviral agent | 英安塔制药有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-107849034-B | EGFR inhibitors and methods of use thereof | 达纳－法伯癌症研究所公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113301897-A | Methods of treating cancer with arene receptor antagonists | 美真达治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113302287-A | Methods for hematopoietic stem and progenitor cell transplantation therapy | 美真达治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-107406442-B | Novel pyrimidines as EGFR inhibitors and methods of treating disorders | 达纳－法伯癌症研究所公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-113271946-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-113260609-A | Aromatic receptor antagonists and methods of use thereof | 美真达治疗公司 | 2021-08-13 | — | — | CN | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-107074859-B | Cyclohexylethyl substituted diaza-and triaza-tricyclics as indoleamine-2, 3-dioxygenase (IDO) antagonists for the treatment of cancer | 默克专利有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230146-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021150806-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3852751-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-20210214339-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-07-15 | — | — | US | disclosed |
| EP-3847159-A2 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | Magenta Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| EP-3843847-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | Merck Patent GmbH (DE) | 2021-07-07 | — | — | EP | disclosed |
| CN-109641892-B | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | 默克专利有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3255047-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND USES IN TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021127282-A1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-11040987-B2 | Penam derivatives for treating bacterial infections | TENNOR THERAPEUTICS LIMITED (CN) | 2021-06-22 | — | — | US | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210179625-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-06-17 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112955142-A | Functionalized heterocyclic compounds as antiviral agents | 英安塔制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2021113795-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3253764-B1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-06-09 | — | — | EP | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112930213-A | Fused imidazopyridines as reversible inhibitors of Bruton's Tyrosine Kinase (BTK) | 默克专利有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| EP-3826999-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme Inc (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3827000-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020422-B2 | Cyclodextrin for the treatment of lysosomal storage diseases | VTESSE LLC | 2021-06-01 | — | — | US | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
| US-11008304-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112739690-A | Pyridin-2-one compounds as SMARCA2 antagonists | 埃皮兹姆公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10987338-B2 | Composition containing artesunate | ZHAO MING (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988458-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-20210115060-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115057-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
| CN-107106575-B | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | 英安塔制药有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2021066922-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210100908-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968249-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210094913-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10961272-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| CN-112585132-A | Proteasome activity enhancing compounds | 蛋白质平衡治疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112585130-A | Proteasome activity enhancing compounds | 蛋白质平衡治疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20210085688-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10952978-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-107207476-B | Indole and azaindole derivatives and their use in neurodegenerative diseases | 默克专利有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20210079014-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210078977-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210079011-A1 | ARTEMISININ-DERIVED TRIMERS AND TETRAMERS AND THEIR USE THEREOF | ZHAO MING (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2021048613-A2 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-18 | — | — | WO | disclosed |
| US-20210077469-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-10947213-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947264-B2 | Process for preparation of sulfonylurea bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-112513024-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-11 | — | — | US | disclosed |
| US-10941152-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | ARES TRADING S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| CN-107865968-B | Cyclodextrins for the treatment of lysosomal storage disorders | 美国政府(由卫生和人类服务部的部长所代表) | 2021-03-05 | — | — | CN | disclosed |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-108699077-B | Heterocyclic compounds as RSV inhibitors | 英安塔制药有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-10934306-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210054020-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10925868-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925967-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-10919900-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20210040088-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040093-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| CN-104829688-B | Macrocyclic proline derived HCV serine protease inhibitors | 益安药业 | 2021-02-09 | — | — | CN | disclosed |
| US-20210030832-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| CN-112312905-A | Tetrazole-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10906895-B2 | Processes for the preparation of benzodiazepine derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10899768-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10899751-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| CN-112236429-A | Heteroaryl compounds as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-112236417-A | Cyanoquinoline amide compounds as HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210008057-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210002255-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002256-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002230-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20210002371-A1 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND IDO1 INHIBITOR FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3755330-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755338-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755689-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755697-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755698-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3755690-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-107428765-B | Pyridazinone macrocyclic compounds used as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-3752517-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3752518-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10870636-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200390783-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10865204-B2 | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865211-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865205-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2020247444-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC, (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247561-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC, (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247575-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200385391-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385377-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3746431-A1 | QUINOLINE COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3746426-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200377477-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375999-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377501-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10851070-B2 | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives | ENATA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200369715-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369646-A1 | QUINOLINE COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-10842878-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| CN-111971278-A | Quinoline compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361948-A1 | NEK INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020231917-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232375-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | SILICON SWAT, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232378-A1 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE | SILICON SWAT, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10836750-B1 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-11-17 | — | — | US | disclosed |
| US-10836722-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3735412-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | Magenta Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10829486-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACUETICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-111902411-A | Compositions and methods for expanding hematopoietic stem and progenitor cells and treating inherited metabolic disorders | 美真达治疗公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200347092-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-20200338132-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| EP-3728268-A1 | NEK INHIBITORS AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728229-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331890-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | SILICON VALLEY BANK | 2020-10-22 | — | — | US | disclosed |
| US-20200331889-A1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200323872-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210246-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200317717-A1 | PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200316051-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-10-08 | — | — | US | disclosed |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| WO-2020198214-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200308193-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3713566-A1 | ARTEMISININ-DERIVED TRIMERS AND TETRAMERS AND THEIR USE THEREOF | Zhao, Ming (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3097084-B1 | NEW KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3253763-B1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2020190935-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | Kineta, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-20200299286-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3710009-A1 | PROCESSES FOR THE RESOLUTION OF BENZODIAZEPIN-2-ONE AND BENZOAZEPIN-2-ONE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111683669-A | Compositions and methods for hematopoietic stem and progenitor cell transplantation therapy | 美真达治疗公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| EP-3703715-A1 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | Magenta Therapeutics, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-106573907-B | Quinoline derivatives and their use for neurodegenerative diseases | 默克专利有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-111630036-A | Oxoacridinylacetic acid derivatives and methods of use thereof | 西利康斯瓦特股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-10759816-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| CN-107108561-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10745358-B2 | Oxoacridinyl acetic acid derivatives and methods of use | SILICON SWAT, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-111542597-A | Compositions and methods for expanding hematopoietic stem and progenitor cells | 美真达治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20200255422-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3388436-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3691638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738035-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| CN-107849055-B | Macrocyclic compounds useful as IRAK1/4 inhibitors and uses thereof | 默克专利有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111511729-A | T L R7/8 antagonists and uses thereof | 默克专利股份公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20200247839-A1 | PROCESS FOR PREPARATION OF SULFONYLUREA BILE ACID DERIVATIVES | ENANTA PHARM INC (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3687543-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10729688-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3676267-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3675637-A1 | HEPATITIS B ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111386118-A | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-10702504-B2 | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702528-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| CN-111372583-A | Artemisinin-derived trimers and tetramers and uses thereof | 赵鸣 | 2020-07-03 | — | — | CN | disclosed |
| EP-3223822-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS | ENANTA PHARM INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| CN-111343990-A | Process for resolving benzodiazepine-2-one and benzazepine-2-one derivatives | 英安塔制药有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3670515-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683289-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683316-B2 | Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200181164-A1 | Thienopyranones and Furanopyranones as Checkpoint Inhibitors and Modulators of Anti-Tumor Immunity | SIGNALRX PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-10676500-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| CN-111263586-A | Hepatitis B antiviral agent | 英安塔制药有限公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-111247134-A | Pyrimidine Gk/AkεInhibitor compounds and uses thereof | 默克专利股份公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-111247135-A | Pyrimidine T-K/I-K-P inhibitor compound and application thereof | 默克专利股份公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200170960-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER | UNIV JOHNS HOPKINS (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3655401-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| US-20200157095-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157057-A1 | PROCESSES FOR THE RESOLUTION OF BENZODIAZEPIN-2-ONE AND BENZOAZEPIN-2-ONE DERIVATIVES | ENANTA PHARM INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640511-B2 | Hepatitis B antiviral agents | Enant Pharmaceuticals, Inc. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200123161-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2020-04-23 | — | — | US | disclosed |
| CN-111032655-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3634423-A1 | THIENOPYRANONES AND FURANOPYRANONES AS CHECKPOINT INHIBITORS AND MODULATIORS OF ANTI-TUMOR IMMUNITY | SignalRX Pharmaceuticals, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200102298-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| CN-110944990-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2020-03-31 | — | — | CN | disclosed |
| US-20200095258-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| WO-2020061435-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-10597382-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3621615-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3157917-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200079764-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-03-12 | — | — | US | disclosed |
| US-10584145-B2 | Process for preparation of sulfonylurea bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| CN-110869017-A | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2020043638-A1 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | MERCK PATENT GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| EP-3615532-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2020041417-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3609890-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110809472-A | Process for the preparation of benzodiazepine derivatives | 英安塔制药有限公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-110785419-A | Aromatic receptor antagonists and uses thereof | 美真达治疗公司 | 2020-02-11 | — | — | CN | disclosed |
| US-10550112-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10548878-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023480-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10544122-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-01-28 | — | — | US | disclosed |
| US-10517872-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-12-31 | — | — | US | disclosed |
| CN-110612105-A | Preparation method of carbamate sulfonic acid bile acid derivative | 英安塔制药有限公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-3573619-A1 | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS | SignalRX Pharmaceuticals, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-10493073-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-12-03 | — | — | US | disclosed |
| US-20190343885-A1 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2019-11-14 | — | — | US | disclosed |
| EP-3221306-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| US-10471042-B2 | Composition containing artesunate | ZHAO MING (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472386-B2 | Bile acid derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190337935-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190337923-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190330183-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10457683-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457703-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190321360-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450310-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314407-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| EP-3552664-A1 | PROTEOSTASIS REGULATORS | Proteostasis Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10442788-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308964-A1 | PROCESSES FOR THE PREPARATION OF BENZODIAZEPINE DERIVATIVES | ENANTA PHARM INC (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3544957-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3544959-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3544975-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10407445-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399986-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190262458-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190262459-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2019164932-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164953-A1 | DEGRADERS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164941-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164948-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164945-A1 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019164947-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3528814-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| WO-2019160889-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019160890-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-10385019-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248777-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3524252-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| WO-2019149522-A1 | QUINOLINE COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| US-10369113-B2 | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019148150-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| WO-2019143902-A2 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-10358441-B2 | Processes for the preparation of benzodiazepine derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20190216808-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-10351572-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2019136159-A1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | Magenta Therapeutics Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190209535-A1 | DEGRADATION OF TRIPARTITE MOTIF-CONTAINING PROTEIN 24 (TRIM24) BY CONJUGATION OF TRIM24 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10344046-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194169-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3500569-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10329297-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3497094-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-10323061-B2 | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323060-B2 | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20190177330-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20190177283-A1 | PROCESSES FOR THE RESOLUTION OF BENZODIAZEPIN-2-ONE AND BENZOAZEPIN-2-ONE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177316-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-10308662-B2 | Thienopyranones as kinase and epigenetic inhibitors | Signal Rx Pharmaceuticals., Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2019104247-A1 | ARTEMISININ-DERIVED TRIMERS AND TETRAMERS AND THEIR USE THEREOF | ZHAO MING (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190161449-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | SILICON SWAT, INC. | 2019-05-30 | — | — | US | disclosed |
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190135823-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3474899-A1 | DEGRADATION OF TRIPARTITE MOTIF-CONTAINING PROTEIN 24 (TRIM24) BY CONJUGATION OF TRIM24 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3472156-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266517-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266565-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266528-B2 | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-20190112307-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190111143-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-18 | — | — | US | disclosed |
| EP-3468561-A1 | HEPATITIS B ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106417-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2019071078-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-10253018-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-10246483-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246439-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190092768-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
| US-10239888-B2 | Targeted protein degradation using a mutant E3 ubiquitin ligase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2019046775-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046186-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046271-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10208055-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | TOCOPHERX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208081-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3440084-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-2707101-B1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20190040084-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2019-02-07 | — | — | US | disclosed |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190029996-A1 | composition containing artesunate | ZHAO MING (US) | 2019-01-31 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189846-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2019018354-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3426245-A1 | HEPATITIS B ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10179792-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179131-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174032-B2 | Heterocyclic compound classes for signaling modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2018236971-A1 | SINGLE MOLECULE COMPOUNDS PROVIDING MULTI-TARGET INHIBITION OF PARP AND OTHER PROTEINS AND METHODS OF USE THEREOF | SIGNALRX PHARMACEUTICALS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180369209-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180362501-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180362545-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20180362502-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180354965-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-20180354912-A1 | ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| WO-2018226739-A1 | THIENOPYRANONES AND FURANOPYRANONES AS CHECKPOINT INHIBITORS AND MODULATIORS OF ANTI-TUMOR IMMUNITY | SIGNALRX PHARMACEUTICALS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018226801-A1 | ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| US-10149835-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | Elmore Patent Law Group, P.C. (US) | 2018-12-11 | — | — | US | disclosed |
| US-10144729-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018218042-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218051-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018218044-A2 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS INC (US) | 2018-11-29 | — | — | WO | disclosed |
| US-10138228-B2 | Isoxazole derivatives as FXR agonists and methods of use therof | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10138233-B2 | Imidazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| EP-3402799-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3402479-A1 | COMPOSITION CONTAINING ARTESUNATE | Zhao, Ming (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180327363-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018209354-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180327388-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180327419-A1 | TARGETED PROTEIN DEGRADATION USING A MUTANT E3 UBIQUITIN LIGASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180318299-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
| WO-2018200988-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-3393465-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | Proteostasis Therapeutics, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298013-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2018-10-18 | — | — | US | disclosed |
| WO-2018191476-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388436-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3049417-B1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-10-17 | — | — | EP | disclosed |
| US-20180290975-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20180291058-A1 | Process for Preparation of Sulfonyl Carbamate Bile Acid Derivatives | ENANTA PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20180273574-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2018-09-27 | — | — | US | disclosed |
| US-10081637-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-10080741-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-10080743-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-10081639-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-10080742-B2 | Isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180258102-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237471-A1 | BILE ACID DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-08-23 | — | — | US | disclosed |
| WO-2018152171-A1 | BILE ACID DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| WO-2018152413-A1 | PROCESSES FOR THE PREPARATION OF BENZODIAZEPINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20180237413-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-20180237425-A1 | PROCESSES FOR THE PREPARATION OF BENZODIAZEPINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2018140730-A1 | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS | SIGNALRX PHARMACEUTICALS, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180214419-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-10034893-B2 | 5, 6-D2 uridine nucleoside/tide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3350170-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| EP-3350177-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-10030013-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-07-24 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180194758-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018129287-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017503-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10005784-B2 | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-26 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180162854-A1 | Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148469-A1 | PROCESS FOR PREPARATION OF SULFONYLUREA BILE ACID DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2018-05-31 | — | — | US | disclosed |
| WO-2018098288-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098280-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098275-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-3324977-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325474-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325469-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9975902-B2 | Compounds for the inhibition of cyclophilins and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| WO-2018089736-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| EP-3319960-A1 | PYRIMIDINE DERIVATIVES AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-9969710-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-15 | — | — | US | disclosed |
| US-20180127424-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20180127400-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2018-05-10 | — | — | US | disclosed |
| EP-3317273-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| EP-3313834-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018075608-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180110798-A1 | CYCLODEXTRIN FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | MALLINCKRODT LLC | 2018-04-26 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018064589-A1 | TARGETED PROTEIN DEGRADATION USING A MUTANT E3 UBIQUITIN LIGASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9931324-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| US-9930893-B2 | Inhibitors of DXP synthase and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-04-03 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2018039310-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2018035080-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | WO | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
| WO-2018031434-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-15 | — | — | WO | disclosed |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180002327-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-9856249-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017223415-A1 | DEGRADATION OF TRIPARTITE MOTIF-CONTAINING PROTEIN 24 (TRIM24) BY CONJUGATION OF TRIM24 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017223188-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170362204-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3256134-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017214395-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
| US-20170334894-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201152-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333399-A1 | Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201155-A1 | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201150-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170334925-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| WO-2017189652-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017189651-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017189663-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| EP-3237411-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170304272-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017185031-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) BY CONJUGATION OF CDK4/6 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017185034-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017185023-A1 | DEGRADATION OF CYCLIN-DEPENDENT KINASE 9 (CDK9) BY CONJUGATION OF CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304270-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017185036-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170304271-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| EP-3230737-A1 | ASSAYS FOR BTK INHIBITORS | Merck Patent GmbH (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9790219-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790221-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| WO-2017177092-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283425-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283426-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3223822-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3223823-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9777006-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776963-B2 | Small molecule CD4 mimetics and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| EP-3221306-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017155844-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3215179-A1 | BILE ACID ANALOGS AN FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017147174-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147159-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147137-A1 | BENZOIC ACID DERIVATIVES OF BILE ACID AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | disclosed |
| US-9745292-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170240587-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240586-A1 | Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9738648-B2 | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226113-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017136403-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9718851-B2 | Deuterated nucleoside/tide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017123884-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017124045-A1 | COMPOSITION CONTAINING ARTESUNATE | ZHAO MING (US) | 2017-07-20 | — | — | WO | disclosed |
| EP-2806875-B1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9708255-B2 | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | Casero, Robert A. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2017112853-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9678083-B2 | Protected amine labels and use in detecting analytes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9669095-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3169678-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | Merck Patent GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20170135961-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-18 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3157917-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9624246-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20170101418-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| EP-3152192-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | Merck Patent GmbH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017045750-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081307-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017049069-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170042882-A1 | Selective Opioid Compounds | ALKERMES INC (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2017019589-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017015451-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015449-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015363-A1 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170014408-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-19 | — | — | US | disclosed |
| WO-2017011552-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-3116501-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-3116870-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-9546166-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| WO-2017007987-A1 | PYRIMIDINE DERIVATIVES AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008857-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539303-B2 | Treatment of Ras-expressing tumors | CELGENE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2017004383-A1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001991-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
| WO-2017003995-A1 | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-9527805-B2 | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-27 | — | — | US | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3105224-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| EP-3097084-A1 | NEW KALLIKREIN 7 INHIBITORS | Sixera Pharma AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| US-9505780-B2 | Thienopyranones as kinase and epigenetic inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2016183266-A1 | EHPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-3092225-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | Merck Patent GmbH (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3090748-A1 | COMPOSITIONS COMPRISING NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | Spring Bank Pharmaceuticals, Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464064-B2 | HCV helicase inhibitors and methods of use thereof | UNIVERSITY OF KANSAS (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2016161268-A1 | HEPATITIS B ANTVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161145-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289262-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20160251387-A1 | SYNTHESIS OF 1-ALKYL-2-AMINO-IMIDAZOL-5-CARBOXYLIC ACID ESTER VIA CALPHA-SUBSTITUTED N-ALKYL-GLYCINE ESTER DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422234-B2 | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2016130809-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| EP-3055295-A1 | SYNTHESIS OF 1-ALKYL-2-AMINO-IMIDAZOL-5-CARBOXYLIC ACID ESTER VIA CALPHA-SUBSTITUTED N-ALKYL-GLYCINE ESTER DERIVATIVES | Merck Patent GmbH (DE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2429568-B1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160229871-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229886-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2016127024-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016127025-A1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160222034-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-3049417-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-9399647-B2 | Proteasome activity modulating compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| WO-2016115090-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-3038626-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | Enanta Pharmaceuticals, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2016105468-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105477-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLTHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016105485-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105525-A2 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105484-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094628-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | WO | disclosed |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160159804-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2016086134-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086115-A1 | TETRAZOLE DERIVATIVES OF BILE ACIDS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2016086218-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086169-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160152609-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160145252-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145295-A1 | TETRAZOLE DERIVATIVES OF BILE ACIDS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145298-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2016081679-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | WO | disclosed |
| US-20160145296-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9346785-B2 | Process for making HCV protease inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| EP-3020723-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160130304-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160130297-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| WO-2016073756-A1 | DEUTERATED NUCLEOSIDE/TIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073480-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073767-A1 | BILE ACID ANALOGS AN FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160130294-A1 | DEUTERATED NUCLEOSIDE/TIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| EP-3013823-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | Merck Patent GmbH (DE) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013341-A1 | METHODS OF MODULATING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013832-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | Merck Patent GmbH (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9328117-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160082004-A1 | Selective Opioid Compounds | ALKERMES INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068534-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068524-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-1968612-B1 | DINUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| WO-2016033164-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160051625-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9259452-B2 | Deacetylase inhibitor therapy | GELGENE CORPORATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160039842-A1 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | EPIGENETIX, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9242974-B2 | Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016009076-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2968311-A2 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | Epigenetix, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970317-A2 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968265-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970309-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968264-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2721031-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2802595-B1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344494-A1 | Thienopyranones as Kinase and Epigenetic Inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-9193740-B2 | Bismacrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315207-A1 | Novel Heterocyclic Compound Classes for Signaling Modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9156886-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-9138442-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2015138934-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138909-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-9127044-B2 | Cyclic depsipeptides | NOVARTIS AG (CH) | 2015-09-08 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2015123174-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225430-A1 | INHIBITORS OF DXP SYNTHASE AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| EP-2903988-A1 | COMPOUNDS USEFUL FOR MAKING HCV PROTEASE INHIBITORS | AbbVie Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015116248-A1 | 5, 6-D2 URIDINE NUCLEOSIDE/TIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150216895-A1 | CYCLODEXTRIN FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-08-06 | — | — | US | disclosed |
| WO-2015112079-A1 | NEW KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2015-07-30 | — | — | WO | disclosed |
| US-9090568-B2 | Quinazolinediones and their use | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
| US-20150182585-A1 | DEACETYLASE INHIBITOR THERAPY | CELGENE CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-9060971-B2 | Combination pharmaceutical agents as inhibitors of HCV replication | ENANTA PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166567-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166565-A1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040552-B2 | Selective opioid compounds | ALKERMES, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015051921-A1 | SYNTHESIS OF 1-ALKYL-2-AMINO-IMIDAZOL-5-CARBOXYLIC ACID ESTER VIA CALPHA-SUBSTITUTED N-ALKYL-GLYCINE ESTER DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-04-16 | — | — | WO | disclosed |
| US-9000020-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8957027-B2 | Deacetylase inhibitor therapy | CELGENE CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2015017382-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017502-A1 | PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8936781-B2 | Macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8927709-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927739-B2 | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209980-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209978-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
| US-8921573-B2 | Processes for the preparation of novel benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8906853-B2 | [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2806876-A2 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2806875-A1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2805726-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2802595-A1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | AbbVie Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140329792-A1 | SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS | UNITED STATE OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVICES (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140323554-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140316143-A1 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140308243-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2468285-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140296243-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014159343-A1 | METHOD OF STIMULATING IMMUNE CELL MIGRATION | CELTAXSYS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8846638-B2 | Macrocyclic nucleoside phosphoramidate derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014152536-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152518-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| WO-2014152029-A2 | OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS | EPIGENETIX, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152229-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014145909-A2 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2768825-A2 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2768517-A2 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2014127378-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140227225-A1 | HCV Helicase Inhibitors and Methods of Use Thereof | UWM RESEARCH FOUNDATION, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140219958-A1 | 5, 6-D2 URIDINE NUCLEOSIDE/TIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8785487-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778938-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187793-A1 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140154208-A1 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014058794-A1 | COMPOUNDS USEFUL FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2709455-A2 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2707101-A1 | PROTEOSTASIS REGULATORS | Proteostasis Therapeutics, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140073797-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2705039-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8664237-B2 | Spiperone derivatives and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-04 | — | — | US | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8648037-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-8642538-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8637561-B2 | Linked diimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2686342-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011857-A1 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8623814-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20140005215-A1 | Selective Opioid Compounds | ALKERMES, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20140005122-A1 | GEMCITABINE COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-8609648-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130315864-A1 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013173759-A2 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130295049-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2658859-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2658858-A2 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8575119-B2 | 2′-chloroacetylenyl substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2651412-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8552162-B2 | Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8501682-B2 | Difluorinated tripeptides as HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501681-B2 | Macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013112706-A1 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013112651-A2 | PROTEASOME ACTIVITY MODULATING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013112699-A2 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| EP-2618831-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183267-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013106631-A1 | PROCESSES FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178630-A1 | PROCESS FOR MAKING HCV PROTEASE INHIBITORS | ABBVIE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2611451-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8481483-B2 | Cyclosporin analogues | ENANTA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130172267-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2603080-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130144036-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013059278-A2 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059281-A2 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-8426458-B2 | Hepatitis C Virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426360-B2 | Carbocyclic oxime hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8420596-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420686-B2 | Linked diimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2013052369-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013052362-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2575819-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2576564-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8415305-B2 | Use of cyclic depsipeptides to inhibit kallikrein 7 | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20130078217-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013044030-A1 | 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013036749-A1 | HCV HELICASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF KANSAS (US) | 2013-03-14 | — | — | WO | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383583-B2 | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8377872-B2 | Non-structural protein-3 (NS-3) protease inhibitors; viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2555622-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367053-B2 | Cyclosporin analogues | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367618-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2542074-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | Enanta Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8349312-B2 | Proline substituted cyclosporin analogues | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120322877-A1 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-12-20 | — | — | US | disclosed |
| WO-2012174487-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| EP-2528436-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8324155-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120302520-A1 | GEMCITABINE COMBINATION THERAPY | CELGENE CORPORATION | 2012-11-29 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012158861-A2 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8314135-B2 | Linked dibenzimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154880-A1 | PROTEOSTASIS REGULATORS FOR TREATING CYSTIC FIBROSIS AND OTHER PROTEIN MISFOLDING DISEASES | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2512480-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120264709-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012142245-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE GOVERNMENT OF THE UNITED OF AMERIA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258886-A1 | PROTECTED AMINE LABELS AND USE IN DETECTING ANALYTES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8283309-B2 | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273709-B2 | Triazole-containing macrocyclic HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| WO-2012125900-A1 | 2'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120214824-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-08-23 | — | — | US | disclosed |
| EP-2488492-A2 | PROTECTED AMINE LABELS AND USE IN DETECTING ANALYTES | Dana-Farber Cancer Institute, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120196792-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196790-A1 | CYCLIC DEPSIPEPTIDES | NOVARTIS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2475256-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2475254-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8222203-B2 | Macrocyclic oximyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2012092409-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARARMACEUTICALS, INC (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012092411-A2 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| US-8211891-B2 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2468287-A1 | Macrocyclic hepatitis c serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2467359-A2 | (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | The Johns Hopkins University (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468285-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468286-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082862-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012078902-A2 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078909-A1 | THIAZOLPYRIMIDINE PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120122834-A1 | SMALL MOLECULE CD4 MIMETICS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178650-B2 | Cyclic depsipeptides | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2012040167-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| EP-2429568-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012030626-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2421532-A2 | SPIPERONE DERIVATIVES AND METHODS OF TREATING DISORDERS | The Johns Hopkins University (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012021704-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120029005-A1 | SPIPERONE DERIVATIVES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120003156-A1 | METHODS FOR TREATING NEOPLASIA BY INHIBITING LACTATE DEHYDROGENASE AND/OR NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2400846-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011156337-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2393359-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301163-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2391376-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | Enanta Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2379559-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| WO-2011127350-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-8030307-B2 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| WO-2011109037-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | ENANTA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110217261-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110206637-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110200677-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| EP-2350012-A2 | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | The Johns Hopkins University (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2340029-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110124649-A1 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123496-A1 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2011049908-A2 | BISMACROKYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047192-A2 | PROTECTED AMINE LABELS AND USE IN DETECTING ANALYTES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110092437-A1 | USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7 | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-7919627-B2 | Synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine derivatives by protecting the hydroxyl group of (6-chloro-pyridin-3-yl)-methanol, reacting with pyrazole, and reacting with hydroxylamine or a derivative or an oxime | ENANTA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910558-B2 | therapy for gramnegative bacteria; antibiotics | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-7906513-B2 | Prevent reproduction; breaking life cycle;viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110053856-A1 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 | GLOUCESTER PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2011022489-A2 | (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20110033420-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2011017519-A2 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-7884099-B2 | such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections | CUMBRE IP VENTURES, L.P. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20110008286-A1 | NOVEL PROLINE SUBSTITUTED CYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008285-A1 | NOVEL CYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008284-A1 | NOVEL CLYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| EP-2271351-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2268619-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2254892-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | Global Alliance For Tb Drug Development (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7842813-B2 | for synthesis of erythromycin derivatives; reacting thionyl chloride with 6-hydroxylmethyl-nicotinic acid methyl ester to provide 6-chloromethyl-nicotinic acid methyl ester, chlorinating, reacting with ammonia or ammonium hydroxide, sulfiding | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2010132163-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100226882-A1 | LINKED DIIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| EP-2224801-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100221216-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-2219453-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100209390-A1 | CYCLOSPORIN ANALOGUES | ENANTA PHARMACEUTICALS, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010088573-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2203435-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | Enanta Pharmaceuticals, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100135960-A1 | ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137239-A1 | GEMCITABINE COMBINATION THERAPY | GLOUCESTER PHARMACEUTICALS (US) | 2010-06-03 | — | — | US | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2010059418-A1 | SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7718612-B2 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-2178821-A2 | HORMONE SENSITIVE LIPASE MODULATORS AND METHODS OF USE | Deviris Inc. (VG) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010042163-A2 | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010039260-A2 | SPIPERONE DERIVATIVES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20100074863-A1 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010030359-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARJMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030858-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100003214-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090305956-A1 | Treatment of Ras-Expressing Tumors | GLOUCESTER PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| WO-2009146123-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090281293-A1 | PROCESSES FOR THE PREPARATION OF 2 FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137739-A1 | PROCESSES FOR THE PREPARATION OF O-[5-[4-AMINO-THIAZOL-2-YL]-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137787-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281324-A1 | PROCESSES FOR THE PREPARATION OF O-[5-(4-AMINO-THIAZOL-2-YL)-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| WO-2009134987-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090274686-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7612045-B2 | Compounds, compositions and methods for controlling biofilms and bacterial infections | SEQUOIA SCIENCES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2009120789-A1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-09-17 | — | — | US | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7582605-B2 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090214650-A1 | Methods of Treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers | ALKERMES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209569-A1 | SELECTIVE OPIOID COMPOUNDS | ALKERMES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2012801-A4 | GEMCITABINE COMBINATION THERAPY | GLOUCESTER PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090191151-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090180985-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180984-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090180983-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090175822-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| WO-2009085978-A1 | BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARCEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009079352-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009079353-A1 | TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156472-A1 | Cyclic Depsipeptides | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2009075923-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090149491-A1 | CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2066326-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2009070689-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070302-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070692-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143373-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7538225-B2 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009064792-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064953-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064388-A2 | INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS | LIU JUN O (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064975-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131343-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090123423-A1 | HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123425-A1 | MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2009053828-A2 | P3 HYDROXYAMINO MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-2049139-A2 | TREATMENT OF RAS-EXPRESSING TUMORS | Gloucester Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7517859-B2 | Spirocyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2009039177-A1 | 6, 11-BICYCLOIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| EP-2037947-A2 | MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090053175-A1 | SUBSTITUTE PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035267-A1 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035268-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-2015763-A2 | COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF MEDICAL CONDITIONS BY MODULATING HORMONE-SENSITIVE LIPASE ACTIVITY | Deviris Inc. (VG) | 2009-01-21 | — | — | EP | disclosed |
| US-20090018189-A1 | Hormone Sensitive Lipase Modulators And Methods Of Use | DEVIRIS | 2009-01-15 | — | — | US | disclosed |
| WO-2009009287-A2 | HORMONE SENSITIVE LIPASE MODULATORS AND METHODS OF USE | DEVIRIS INC. (VG) | 2009-01-15 | — | — | WO | disclosed |
| EP-2012801-A2 | GEMCITABINE COMBINATION THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009003009-A1 | SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080292587-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080287449-A1 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080279821-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080274082-A1 | OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR | ENANTA PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080274080-A1 | AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008134397-A1 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134398-A1 | OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267917-A1 | N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1983828-A2 | UBIQUITIN/PROTEASOME INHIBITORS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1983991-A2 | METHODS OF TREATING ALCOHOLISM AND ALCOHOL RELATED DISORDERS USING COMBINATION DRUG THERAPY AND SWELLABLE POLYMERS | Alkermes, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008127659-A2 | COMBINATION THERAPY FOR CANCER | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-20080242865-A1 | PROCESSES FOR THE PREPARATION OF HYDROXYLAMINES | TANG DATONG | 2008-10-02 | — | — | US | disclosed |
| EP-1968612-A2 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1965824-A2 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 | Gloucester Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7414030-B2 | 6-11 Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-7402568-B2 | synthetic macrolides useful in the treatment and prevention of bacterial infections | ENANTA PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080145322-A1 | Componds, Composition and Method for Controlling Biofolms and Bacterail Infections | SEQUOIA SCIENCES, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080124403-A1 | DEACETYLASE INHIBITOR THERAPY | GLOUCESTER PHARMACEUTICALS | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008021956-A2 | ACYLAMINOHETEROARYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021871-A2 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008022006-A2 | ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021733-A2 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008019240-A2 | 3, 6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008019266-A2 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| EP-1885737-A2 | 6-11 BRIDGED OXIME ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013589-A2 | TREATMENT OF RAS-EXPRESSING TUMORS | GLOUCESTER PHARMACEUTICALS (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299129-A1 | Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity | DEVIRIS INC. (VG) | 2007-12-27 | — | — | US | disclosed |
| US-7312201-B2 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145704-A2 | GEMCITABINE COMBINATION THERAPY | GLOUCESTER PHARMACEUTICALS (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007143694-A2 | MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007070598-A9 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK (US) | 2007-11-08 | — | — | WO | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007097980-A9 | UBIQUITIN/PROTEASOME INHIBITORS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7271155-B2 | 9A, 11-2C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207144-A1 | Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy | SMA FOUNDATION | 2007-09-06 | — | — | US | disclosed |
| US-7265094-B2 | 9N-substituted 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265107-B2 | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007097980-A2 | UBIQUITIN/PROTEASOME INHIBITORS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | SMA FOUNDATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-7256187-B2 | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-08-14 | — | — | US | disclosed |
| WO-2007089934-A2 | METHODS OF TREATING ALCOHOLISM AND ALCOHOL RELATED DISORDERS USING COMBINATION DRUG THERAPY AND SWELLABLE POLYMERS | ALKERMES, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-7250413-B2 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2007081808-A2 | COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF MEDICAL CONDITIONS BY MODULATING HORMONE-SENSITIVE LIPASE ACTIVITY | DEVIRIS INC. (VG) | 2007-07-19 | — | — | WO | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007070598-A2 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1797108-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | Eldridge, Gary R. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129290-A1 | Metabolite derivatives of the HDAC inhibitor FK228 | GLOUCESTER PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007061939-A2 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007056300-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BRAIN REWARD SYSTEM DISORDERS BY COMBINATION THERAPY | ALKERMES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099947-A1 | Methods and compositions for the treatment of brain reward system disorders by combination therapy | ALKERMES, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2007044927-A2 | 6, 11-BRIDGED TRICYCLIC MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1723150-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7135573-B2 | Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| WO-2006119313-A2 | 6-11 BRIDGED OXIME ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119384-A1 | SPIROCYCLIC BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252713-A1 | Spirocyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060252712-A1 | 6-11 Bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060252710-A1 | Bicyclic 12 lactone ring macrolide, ketolide, and anhydrolide derivatives; antibacterial; cystic fibrosis | ENANTA PHARMACEUTICALS, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060247440-A1 | Processes for the preparation of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20060183802-A1 | Compositions and methods for treating amyotrophic lateral sclerosis (ALS) | COLON WILFREDO | 2006-08-17 | — | — | US | disclosed |
| WO-2005027962-A9 | 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006078450-A1 | 9A, 11-2C-BICYCLIC 9A-AZALIDE DERIVATIVES | ENANTA PHARMACUETICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060154881-A1 | 9A,11-2C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060148731-A1 | 11,12-Lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060142215-A1 | Tetracyclic bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006065721-A2 | 11, 12-LACTONE BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065743-A2 | TETRACYLIC BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-7064110-B2 | 6-11 bicycle ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122128-A1 | 3,6-Bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1646638-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006039263-A2 | NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-7022679-B2 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060069048-A1 | Novel bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. | 2006-03-30 | — | — | US | disclosed |
| WO-2006031943-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | ELDRIDGE GARY R (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058248-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | XU GUOYOU | 2006-03-16 | — | — | US | disclosed |
| US-20060058247-A1 | Methods and compositions for treating cystic fibrosis | ENANTA PHARMACEUTICALS, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20050282758-A1 | 6-11 Bicyclic ketolide derivatives | NIU DEQIANG | 2005-12-22 | — | — | US | disclosed |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | CUMBRE INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050256096-A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6953782-B2 | 11-C-substituted erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050203085-A1 | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050203076-A1 | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005080408-A1 | BRIDGED MACROCYCLIC COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187169-A1 | 6-11 Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005077040-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005070941-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050171033-A1 | 9N-substituted 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070113-A2 | 9N-SUBSTITUTED 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070918-A1 | PROCESS FOR THE PREPARATION OF T-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005067564-A2 | 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005067919-A1 | 11-CSUBSITUTED ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005061526-A1 | 6-11 BICYCLIC KETOLIDE DRIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061525-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143326-A1 | 11-C-substituted erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | IONIS PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050065073-A1 | Aza-peptide macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1506214-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050009761-A1 | Bridged macrocyclic compounds and processes for the preparation thereof | ENANTA PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004108745-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108746-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254126-A1 | 11-12 Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157787-A1 | 6-11 Bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003097659-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1089958-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1089958-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |